| Please provide the name and a brief description of your resource |
Resource ABC, brief description |
| Please provide the URL of your resource |
https://my-resource.com |
| Please provide your contact details (Name, surname, e-mail address, function in the organisation) |
Name, surname, myaddress@mail.com, function |
| Type of resource |
Public (academic/institutional) |
| Essential requirement: Does your resource directly contribute to one or more of ERDERA’s general (GO) or specific (SO) objectives? |
- SO5: Integrated multinational & multi-stakeholder R&I ecosystem for rare diseases - GO2: New effective therapies for rare diseases approved in the EU and beyond - GO1: Diagnosis established or enrolment in systematic research in average within 6 months after coming to medical attention (in EU and Associated countries) |
| Essential requirement: Is your resource dedicated to rare diseases (RD), or does it contain data or services that could be adapted to support RD research? |
Unanswered |
| Has your resource already followed an assessment process? |
Unanswered |
| If you answered 'Yes, via another resource' to the previous question, please specify below: |
Unanswered |
| Is your resource relevant to RD Research? |
Unanswered |
| Would you like to utilise the VP as a platform to enhance the visibility of your resource or enterprise for publicity or commercial purposes? |
Unanswered |
| Is access to your resource governed by clearly defined agreements, such as a Terms of Use? |
Unanswered |
| Is your resource Open Source through a recognised repository (such as GitHub, GitBucket or SourceForge)? |
Unanswered |
| Does your resource follow the FAIR (Findable, Accessible, Interoperable, Reusable) data principles? |
Unanswered |
| Does your resource include established oversight protocols via a Scientific Advisory Body or another similar body? |
Unanswered |
| Is your resource free to use? |
Unanswered |
| Is your resource peer reviewed, for example, by peers, by users, or by independent bodies (such as ELIXIR CDR) |
Unanswered |
| Does your resource include any of the following functionalities / components? |
No Choices Selected |
| If you answered anything other than 'No' in the previous question, please specify your response |
Unanswered |
| How is the technical performance of your resource, if applicable, in terms of average % uptime per month over the last year, or in terms of response time or any other measure? |
Unanswered |
| How is access security managed (ex. using AAI...)? |
Unanswered |
| Regarding the installation of your resource, is it: |
Unanswered |
| Please describe the intuitive interface of your resource in terms of: |
Unanswered |
| Is the command line of your resource modifiable to particular or non-standard requirements? |
Unanswered |
| Is your resource scalable / automatable in that it is interoperable and can be incorporated into a pipeline / workflow? |
Unanswered |
| Are the file formats of you resource: |
Unanswered |
| Clear processing |
Unanswered |
| If you selected 'Other' in the question above, please specify |
Unanswered |
| Please elaborate on the release cycle of you resource and specify if a permanent archive of releases exists |
Unanswered |
| Which kind of support does your resource provide to end-users? |
Unanswered |
| If you selected 'Other' in the question above, please specify |
Unanswered |
| How are issues such as troubleshooting, bug reports, and new feature requests addressed? |
Unanswered |
| How is maintenance governed? |
SOPs |
| Does your resource have any training materials available such as user documentation, webinars etc? Please specify below |
training material 1, training material 2... |
| Is your resource included in a registry? |
Registry, findable by... |
Questionnaire Answers: DSH service provision form feedback
Below are the responses submitted for the questionnaire.
Table of Contents
Self-Assessment to Join the Virtual Platform Curated Network
- SO5: Integrated multinational & multi-stakeholder R&I ecosystem for rare diseases
- GO2: New effective therapies for rare diseases approved in the EU and beyond
- GO1: Diagnosis established or enrolment in systematic research in average within 6 months after coming to medical attention (in EU and Associated countries)
Motivation and Scope
Data analysis facilities
Reference datasets
Objectives of co-creation
General information on data
Current status of the data
- None of the above
- Phenopackets (https://phenopacket-schema.readthedocs.io/)